SARS-CoV-2

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 11, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Marketing, Immunodeficiency, INN, Risk, Sensation, Messenger, Nausea, RMP, Alpha, Myocarditis, Vaccination, Heart, Inflammation, Assessment, SARS, Fever, Anatomy, Paresthesia, IIA, Hypoesthesia, Skin, COVID-19 vaccine, Fatigue, ATC, Red, Pain, Ageing, Republic, Omicron, Allergy, Tenderness, Pregnancy, Safety, Medical Subject Headings, Group, Immune system, Antibody, EMA, International, Injection, Language, Select, Patient, Originality, Vomiting, Pericarditis, Anaphylaxis, System, Vaccine, Headache, Clinical trial, Swelling, Temperature, COVID-19, European Medicines Agency, SARS-CoV-2, Rash

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 11, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir,ritonavir, Date of authorisation: 28/01/2022, Revision: 16, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Death, ATC, Antibody, Depression, COVID 19, International, Headache, Disease, Language, Blood, PF-07321332, Mouth, Omicron, COVID, COVID-19, European Medicines Agency, Ritonavir, Tablet, SARS-CoV-2, Select, Patient, Diagnosis, Anatomy, Vomiting, IIA, Viral, Medical device

Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir,ritonavir, Date of authorisation: 28/01/2022, Revision: 16, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir,ritonavir, Date of authorisation: 28/01/2022, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Marketing, Immunodeficiency, INN, Risk, Sensation, Messenger, Delta, Nausea, RMP, Vaccination, Heart, Inflammation, Back pain, SARS, Hardness, Bruise, Anatomy, IIA, Odynophagia, Hypoesthesia, Skin, Chills, Diarrhea, Fever, Fatigue, ATC, Pain, Ageing, Pregnancy, Somnolence, Arthralgia, Medical Subject Headings, Agency, Immune system, Allergy, Antibody, EMA, International, Language, Pfizer–BioNTech COVID-19 vaccine, Dizziness, Select, Patient, Vomiting, Erythema, Pericarditis, Lymph, System, Vaccine, Weakness, Headache, Abdominal pain, Swelling, Hypersensitivity, Temperature, COVID-19, SARS-CoV-2, Myalgia, Paresthesia, Rash

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 3, Status: Authorised

TechImmune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 2, 2024
Conference, Antigen, Pandemic, COV, Vaccine, University, J. P. Morgan, COVID, COVID-19, Immunity, SARS-CoV-2

Dr. Ulmer will present a company overview on Wednesday, January 10th at 1:30 PM PST.

Key Points: 
  • Dr. Ulmer will present a company overview on Wednesday, January 10th at 1:30 PM PST.
  • Institutional investors who are interested in attending the presentation should contact their J.P. Morgan representative for registration information.
  • Current vaccines for COVID-19 rely upon immunizing subjects with vaccines targeting the virus surface Spike protein of SARS-CoV-2 for induction of protective antibody responses.
  • Such a broad-spectrum COVID vaccine would obviate the need for frequent updating and boosting, as well as prevent future outbreaks.

EQS-News: Marinomed Biotech AG with new Carragelose distribution and manufacturing partners and EU patent

Retrieved on: 
Saturday, December 30, 2023
Partnership, News, Patent, DKSH, Infection, SARS-CoV-2, European Patent Convention, Pharmaceutical industry

DKSH is a leading Market Expansion Services provider with nearly 160 years of experience, operating in 37 markets globally.

Key Points: 
  • DKSH is a leading Market Expansion Services provider with nearly 160 years of experience, operating in 37 markets globally.
  • Moreover, Marinomed was also able to successfully establish the production of Carragelose lozenges with its new Turkish manufacturing partner Meksmar.
  • Marinomed already supplied first customers with products and plans to further expand the distribution of Carragelose lozenges in the future.
  • Ending the year with a new partnership, a European patent and a successful manufacturing process shows once more that Carragelose is a success story,” Andreas Grassauer, CEO of Marinomed, says.

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

Retrieved on: 
Tuesday, December 19, 2023
Mpox, HHS, Infection, Immune system, Biotechnology, NIAID, Virus, License, Vaccine, Patent, Disease, City, COH, GeoVax, COVID-19, Cancer, Smallpox, Bangladesh Technical Education Board, HIV, SARS-CoV-2, Orthopoxvirus, NIH, Immunization, MVA

The amendment expands GeoVax’s commercial license to include Mpox and smallpox as additional indications.

Key Points: 
  • The amendment expands GeoVax’s commercial license to include Mpox and smallpox as additional indications.
  • Modified Vaccinia Ankara (MVA) is the vaccine currently used and stockpiled in the U.S. Strategic National Stockpile for immunization against the Mpox and smallpox viruses.
  • The addition of the Mpox and smallpox indications to our NIAID License Agreement complements GeoVax’s license agreement with COH for GEO-CM04S1, which we also recently amended to obtain development and commercialization rights against orthopoxviruses in addition to SARS-CoV-2.
  • For those regions/populations where Mpox and/or smallpox may be of a concern, we believe our COVID-19 vaccine will be a better choice.”

Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

Retrieved on: 
Monday, December 18, 2023
Immunodeficiency, IC50, FDA, Half-life, Clinical trial, IC, COVID-19, Science Translational Medicine, SARS-CoV-2, Safety, Vaccine

“VYD222 produced high serum virus neutralizing antibody (sVNA) titer levels against XBB.1.5 in the IC cohort, essentially replicating the titer levels observed in our Phase 1 clinical trial of VYD222 in healthy volunteers.

Key Points: 
  • “VYD222 produced high serum virus neutralizing antibody (sVNA) titer levels against XBB.1.5 in the IC cohort, essentially replicating the titer levels observed in our Phase 1 clinical trial of VYD222 in healthy volunteers.
  • We are also encouraged by the potential early signal of strong clinical protection from symptomatic COVID-19 in the CANOPY clinical trial to date, which would be expected given the high VYD222 sVNA titer levels and dose selected.
  • We are encouraged by the initial results from CANOPY that we believe are supportive of an immunobridging approach for VYD222.
  • Importantly, VYD222 continues to show neutralizing activity against variants with the F456L mutation that is found in the majority of variants in the U.S. currently.

Ethris Initiates First-in-Human Dosing in Phase 1 Study of ETH47 for the Treatment of Virus-Induced Asthma

Retrieved on: 
Monday, December 18, 2023
LNP, RNA, Biotechnology, Messenger, Lung, Snap, Vaccine, Respiratory failure, Trial of the century, Inhalation, Pharmacokinetics, Asthma, SARS-CoV-2, Patient, Safety, Therapy

ETH47 was also designed to be administered locally to the lung through inhalation or nasal spray using the company’s proprietary Stabilized NanoParticle (SNaP) LNP platform.

Key Points: 
  • ETH47 was also designed to be administered locally to the lung through inhalation or nasal spray using the company’s proprietary Stabilized NanoParticle (SNaP) LNP platform.
  • The Phase 1 study will primarily evaluate ETH47’s safety and tolerability in healthy participants.
  • The program, although initially focused on virus-induced asthma, has the potential to be applied for pandemic preparedness against influenza and SARS-CoV-2 due to its broad applicability.
  • The study will contain 3 parts based on the type of delivery of ETH47, which includes nasal, inhaled and a nasal/inhaled combination.

Microbix & BioGX Collaborate on real-time PCR Assays & Controls

Retrieved on: 
Thursday, December 7, 2023
Herpes simplex, Chickenpox, Mpox, OTCQX, Collection, Business, Applied Biosystems, PCR, Syphilis, Refrigeration, COVID, Business development, SARS-CoV-2, TSX, SVP, Pleasure, XFree86, Treponema pallidum

Microbix was chosen by BioGX to be the primary External Quality Controls provider for assays on their newly-launched pixl platform – a benchtop instrument with capabilities for syndromic testing.

Key Points: 
  • Microbix was chosen by BioGX to be the primary External Quality Controls provider for assays on their newly-launched pixl platform – a benchtop instrument with capabilities for syndromic testing.
  • Microbix QAPs are now referenced in BioGX Assay Product Inserts (available at https://www.biogx.com ), with additional QAPs to be referenced as the collaboration expands.
  • Xfree technology provides a complete lyophilized test in a single tube – using the trusted BioGX Sample-Ready™ format for extraction-free, direct sample addition in real-time PCR testing.
  • Phil Casselli, SVP of Sales & Business Development at Microbix, commented, “It has been a pleasure to work with Robert and his team at BioGX to support their customer base with robust External Quality Controls.

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

Retrieved on: 
Monday, November 27, 2023
Recce, Ross River virus, Simplex, ASX, Government, RCE, Klebsiella pneumoniae, PCT, Virus, Burn, Administration, Streptococcus pneumoniae, Patent, Disease, Staphylococcus aureus, Infection, Gonorrhea, Canada Revenue Agency, Inhalation, Shingles, Pseudomonas aeruginosa, Biology, COVID-19, Streptococcus pyogenes, Viral, EBV, Escherichia coli, HIV, Coronavirus, SARS-CoV-2, Cytomegalovirus, Staphylococcus, Urinary tract infection, Bacteria, Neisseria meningitidis, HCMV, Science, Skin, Pharmaceutical industry

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • In July 2023, the Company received an AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
  • The program is administered by the Canada Revenue Agency and is aimed at incentivizing businesses to conduct R&D in Canada, encouraging innovation and technological advancements.